<DOC>
	<DOCNO>NCT00409409</DOCNO>
	<brief_summary>A phase III study evaluate efficacy safety SLIT grass pollen allergen compare placebo reduction symptom rescue medication usage child .</brief_summary>
	<brief_title>Efficacy Safety 300 IR Sublingual Immunotherapy ( SLIT ) Tablets Children Suffering From Grass Pollen Rhinoconjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Male female outpatient age 5 17 year . Written consent / assent . Grass pollenrelated allergic rhinoconjunctivitis least last two pollen season . Sensitised grass pollen ( positive SPT grass pollenspecific IgE value least Class 2 ) . Total symptom score Retrospective RTSS previous pollen season great equal 12 . Patients receive desensitisation treatment grass pollen .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Sublingual immunotherapy</keyword>
	<keyword>Grass pollen tablet</keyword>
	<keyword>Allergic rhinoconjunctivitis</keyword>
</DOC>